Contact

Indigo Current Home About Services Access Pathways Safety & Risks Policy & Research Tracker Contact U.S. status signal // 2026 Ibogaine Treatment In USA A clear, cautious guide to research, regulation, safety concerns, and changing access pathways around ibogaine in the United States. Evidence first Safety clarity Policy watch 01 // Current signal A pivotal year, not a settled treatment. Ibogaine is a naturally occurring psychoactive indole alkaloid associated with the African shrub Tabernanthe iboga . In the United States, it is not an approved clinical treatment and remains a Schedule I controlled substance. The DEA’s drug scheduling framework explains the federal category that shapes routine access. Interest has nevertheless accelerated around opioid use disorder, PTSD, traumatic brain injury, and treatment-resistant psychiatric conditions. The public conversation is being driven by patient demand, early but limited evidence, serious cardiac risk, and a changing policy posture. Routine U.S. access is not legal. In practice, “ibogaine treatment” can refer to clinical trial participation, narrow investigational pathways, or travel abroad to private clinics. A practical overview of ibogaine treatment in the United States can help distinguish those routes without treating them as equivalent. Key point: The field is moving quickly, but ibogaine should not be presented as established, routine, or low-risk medical care. 02 // Why attention is rising Policy, research, and public need have converged. In 2026, federal and state action has made ibogaine a policy issue rather than a niche psychedelic topic. Texas allocated $50 million for state-backed clinical trials examining ibogaine for addiction, traumatic brain injury, and behavioral health disorders. The work of the Texas Ibogaine Initiative is part of the wider conversation around that state-level momentum. The FDA also allowed the first U.S. clinical study of noribogaine hydrochloride to move forward. That do

A clear line for feedback